Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Talking About Tumors
Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer
All episodes
Best episodes
Seasons
Top 10 Talking About Tumors with Ryann and Ryan - A medical oncology podcast Episodes
Goodpods has curated a list of the 10 best Talking About Tumors with Ryann and Ryan - A medical oncology podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Talking About Tumors with Ryann and Ryan - A medical oncology podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Talking About Tumors with Ryann and Ryan - A medical oncology podcast episode by adding your comments to the episode page.
04_00 Introduction (Updated 12.17.23)
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
12/17/23 • 3 min
We have updated our initial introduction and are re-posting it here as well as in the initial file.
03_13 Head and Neck Cancer – Locally advanced and metastatic
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
11/29/23 • 37 min
1. Role for definitive chemotherapy and radiation
2. Controversy on induction chemotherapy
3. Considerations for nasopharyngeal cancer
4. Approach to metastatic HNSCC
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Burtness B et al. J Clin Oncol. 2022;40(21):2321-2332. doi:10.1200/JCO.21.02198
2. Burtness B et al. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
3. Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656
4. Gibson MK et al. JCO. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057
5. Zhang L et al. Lancet. 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-5
6. Zhang Y et al. NEJM. 2019;381(12):1124-1135. doi:10.1056/NEJMOA1905287
7. Gau M et al. Oral Oncol. 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.015
8. GT W, et al. NEJM. 1991;324(24):1685-1690. doi:10.1056/NEJM199106133242402
9. Lacas B et al. Radiother Oncol. 2021;156:281. doi:10.1016/J.RADONC.2021.01.013
10. Bourhis et al. JCO. 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.5505
11. Gyawali B et al. Cancer Treat Rev. 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.002
12. Forastiere AA et al. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245
13. Posner MR et al. NEJM. 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
01_05 Localized Esophageal and Gastric Cancer
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
05/10/22 • 36 min
1. Anatomy of the Upper GI Tract
2. Diagnosis, Staging Work-up
3. Neoadjuvant Chemoradiation for Esophageal/EGJ
4. Perioperative and Adjuvant Gastric/EGJ
5. Checkmate 577 discussion
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Ronellenfitsch U et al. Eur J Cancer. 2019;123:101-111. doi:10.1016/J.EJCA.2019.10.001
2. Ohn J et al. NEJM 2009;345(10):725-730. doi:10.1056/NEJMOA010187
3. Ell C et al. Gastroenterology. 2000;118(4):670-677. doi:10.1016/S0016-5085(00)70136-3
4. al-Sarraf M et al. J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277
5. Oba K et al. J Natl Cancer Inst. 2013;105(21):1600-1607. doi:10.1093/JNCI/DJT270
6. Bang YJ et al. Lancet. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4
7. Smalley SR et al. Journal of Clinical Oncology. 2012;30(19):2327. doi:10.1200/JCO.2011.36.7136
8. Petrelli F et al. Eur J Cancer. 2017;76:8-16. doi:10.1016/J.EJCA.2017.01.032
9. Kelly RJ et al. NEJM 2021;384(13):1191-1203. doi:10.1056/NEJMOA2032125/
10. Al-Batran SE et al. The Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1
11. al-Sarraf M et al.J Clin Oncol. 1997;15(1):277-284. doi:10.1200/JCO.1997.15.1.277
12. Cunningham D et al. NEJM. 2009;355(1):11-20. doi:10.1056/NEJMOA055531
13. JS C, et al. JAMA. 1999;281(17):535-547. doi:10.1001/JAMA.281.17.1623
14. Park SH et al. J Clin Oncol. 2021;32(3):368-374. doi: 10.1016/j.annonc.2020.11.017
15. Lee J et al. Journal of Clinical Oncology. 2012;30(3):268-273. doi:10.1200/JCO.2011.39.1953
16. Cats A et al. The Lancet Oncology. 2018;19(5):616-628. doi:10.1016/S1470-2045(18)30132-3
20. van Hagen P et al. NEJM. 2012;366(22):2074-2084. doi: 10.1056/NEJMoa1112088
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
01_01 Metastatic Colon Cancer, An Overview of Management and Fundamentals of Systemic Therapy
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
04/04/22 • 26 min
1. Clinical presentations of metastatic colon cancer
2. ECOG performance status
3. 5-fluorouracil and capecitabine
4. Doublet Regimens (FOLFOX/FOLFIRI and derivatives)
5. FOLFOXIRI
6. Considerations for elderly/frail patients
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode
1. Cremolini C, et al. Lancet Oncol. 2020;21(4):497-507. doi:10.1016/S1470-2045(19)30862-9
2. Cremolini C et al. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9
3. Sobrero AF et al. J Clin Oncol. 2016;15(1):368-381. doi:10.1200/JCO.1997.15.1.368
4. Pinedo HM, Peters GFJ. J Clin Oncol. 1988;6(10):1653-1664. doi:10.1200/JCO.1988.6.10.1653
5. Loriot MA, et al. Bulletin du Cancer. 2018;105(4):397-407. doi:10.1016/J.BULCAN.2018.02.001
6. Pachman DR et al. J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533
7. Eonard L et al. NEJM. 2009;343(13):905-914. doi:10.1056/NEJM200009283431302
8. Falcone A et al. J Clin Oncol. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928
9. Tournigand C et al. J Clin Oncol. 2004;22(2):229-237. doi:10.1200/JCO.2004.05.113
10. Group NGTAT. J Clin Oncol. 2016;10(6):904-911. doi:10.1200/JCO.1992.10.6.904
11. Jang RW et al. J Oncol Practice. 2014;10(5):e335-e341. doi:10.1200/JOP.2014.001457
12. Simmonds PC, et al. B J Cancer 2006 94:7. 2006;94(7):982-999. doi:10.1038/sj.bjc.6603033
13. Douillard JY et al. Lancet. 2000;355(9209):1041-1047. doi:10.1016/S0140-6736(00)02034-1
14. de Gramont A et al. J Clin Oncol. 2016;15(2):808-815. doi:10.1200/JCO.1997.15.2.808
15. O’connell MJ. Cancer. 1989;63:1026-1030. doi:10.1002/1097-0142
16. Poon MA et al. J Clin Oncol. 2016;7(10):1407-1418. doi:10.1200/JCO.1989.7.10.1407
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Introduction (Updated 12.17.23)
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
04/04/22 • 3 min
Overview of our podcast and goal.
04_07 Localized Renal Cell Carcinoma
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
07/06/24 • 25 min
1. Risk Factors and Presentation
2. Staging and Paraneoplastic syndromes
3. Localized Therapy Options and Considerations
4. Evidence and Limitations for Adjuvant Systemic Therapy
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG
2. Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/
3. Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0
4. Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0
5. Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025
6. Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/
7. Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
04_08 Metastatic Renal Cell Carcinoma
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
08/02/24 • 24 min
1. Historical Approach (cytoreduction, IFN-a, sunitinib
2. Prognostic risk scores
3. Evidence for modern doublet regimens
4. Later line therapy
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
- Flanigan RC et al. J Urol. 2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae
- Bex A et al. JAMA Oncology. 2019;5(2):164-170. doi:10.1001/jamaoncol.2018.5545
- Mejean A et al. NEJM. 2018;379:417-427. doi:10.1056/NEJMoa1803675
- Motzer RJ et al. NEJM. 2007;356:115-124. doi:10.1056/NEJMoa065044
- Rini BI et al. NEJM. 2019;380:1116-1127. doi:10.1056/NEJMoa1816714
- Rini BI et al. JCO. 2023;41(17 Supp). doi:10.1200/JCO.2023.41.17_suppl.LBA4501
- Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023
- Motzer RJ et al. NEJM. 2018;378:1277-1290. doi:10.1056/NEJMoa1712126
- Motzer R et al. NEJM. 2021;384:1289-1300. doi:10.1056/NEJMoa2035716
- Albiges L et al. Ann Oncol. 2023;34(2 Supp):S1329-S1330. doi:10.1016/j.annonc.2023.10.090
- Jonasch E. ASCO Annual Meeting presented May 31, 2024 in Chicago, IL
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
05_01 Hepatocellular carcinoma
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
12/19/24 • 32 min
1. Etiologies and epidemiology
2. Staging and local/regional considerations
3. Systemic Therapy
4. Differences in immune checkpoint sensitivity by etiology
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183
2. Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0
3. Zhu AX et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9
4. Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070
5. Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1
7. Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857
8. Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018
9. Cheng AL et al. J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030
10. Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/
11. Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
01_10 Localized Cholangiocarcinoma
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
08/04/22 • 21 min
1. Overview of intrahepatic, perihilar, distal cholangiocarcinoma
2. Overview of gall bladder adenocarcinoma
3. Adjuvant chemoradiation and chemotherapy considerations
4. Per-protocol, intention to treat analysis, historical controls
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Bridgewater J, Fletcher P, Palmer DH, et al. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. J Clin Oncol. 2022;40(18):2048-2057. doi:10.1200/JCO.21.02568
2. Primrose JN, Neoptolemos J, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X
3. Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192-202. doi:10.1002/BJS.10776
4. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1). doi:10.1053/J.GASTRO.2012.04.008
5. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(12):1015-1027. doi:10.1200/JCO.18.02178
6. Edeline J, Bonnetain F, Phelip JM, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. https://doi.org/101200/JCO2017354_suppl225. 2017;35(4_suppl):225-225. doi:10.1200/JCO.2017.35.4_SUPPL.225
7. Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-v37. doi:10.1093/ANNONC/MDW324
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
04_04 Castrate Resistant Metastatic Prostate Cancer
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
02/22/24 • 24 min
1. On continuation of ADT and ARAT switch
2. Systemic therapy options after progression
3. Improper mandated crossover
4. PARP inhibitors in prostate cancer
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/
2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/
3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116
4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/
5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6
6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141
7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/
8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
Show more best episodes
Show more best episodes
FAQ
How many episodes does Talking About Tumors with Ryann and Ryan - A medical oncology podcast have?
Talking About Tumors with Ryann and Ryan - A medical oncology podcast currently has 50 episodes available.
What topics does Talking About Tumors with Ryann and Ryan - A medical oncology podcast cover?
The podcast is about Health & Fitness, Cancer, Medicine, Podcasts, Education and Oncology.
What is the most popular episode on Talking About Tumors with Ryann and Ryan - A medical oncology podcast?
The episode title '04_03 Metastatic Castrate Sensitive Prostate Cancer' is the most popular.
What is the average episode length on Talking About Tumors with Ryann and Ryan - A medical oncology podcast?
The average episode length on Talking About Tumors with Ryann and Ryan - A medical oncology podcast is 27 minutes.
How often are episodes of Talking About Tumors with Ryann and Ryan - A medical oncology podcast released?
Episodes of Talking About Tumors with Ryann and Ryan - A medical oncology podcast are typically released every 18 days, 13 hours.
When was the first episode of Talking About Tumors with Ryann and Ryan - A medical oncology podcast?
The first episode of Talking About Tumors with Ryann and Ryan - A medical oncology podcast was released on Apr 4, 2022.
Show more FAQ
Show more FAQ